ArQule announces SPA with FDA for ARQ 197 Phase 3 trial style for NSCLC ArQule.

ArQule announces SPA with FDA for ARQ 197 Phase 3 trial style for NSCLC ArQule, Inc. today announced a particular Protocol Assessment agreement with the U.S http://cialissverige.org/lakemedel-online.html . Food and Medication Administration for the design of a Phase 3 trial of ARQ 197 in patients with non-small cell lung tumor of non-squamous histology. Daiichi Sankyo Co., Ltd., the holder of the Investigational New Medication application for ARQ 197 and ArQule’s partner for the advancement of the substance, will conduct the Stage 3 trial, which is planned for initiation this year later.

cialis 5 mg

Aratana announces $40 million senior secured credit facility Aratana Therapeutics, Inc. , a family pet therapeutics company centered on the licensing, commercialization and development of innovative biopharmaceutical products for companion animals, today announced a $40 million senior secured credit service with Pacific Western Bank, as lender and agent, and Oxford Financing LLC, as loan provider. The service refinances the $15 million loan facility previously supplied to the business by Pacific Western Lender . The brand new facility includes two types of loans, a $35 million term loan and a $5 million revolving loan.

Related Posts

Other Posts From Category "mental":